TY  - JOUR
T1  - BIological warfare
AU  - Peloso PM, Baillie C
Y1  - 1999/11/17
N1  - 10-1001/pubs.JAMA-ISSN-0098-7484-282-19-jbk1117
JO  - JAMA
SP  - 1817
EP  - 1817
VL  - 282
IS  - 19
N2  - 
To the Editor: Bupropion hydrochloride, an
atypical antidepressant that has both dopaminergic and adrenergic actions,
is effective for smoking cessation, being more effective than placebo1 and more effective than the nicotine patch alone.2 Bupropion enhances the response rate of the nicotine
patch. Recent guidelines on smoking cessation3
recommend bupropion for smokers who fail treatment with or who do not wish
to use nicotine replacement therapy. It is the second-line therapy in part
due to adverse effects.4 Principally, these
include agitation, dizziness, insomnia, tremor, reduced seizure threshold,
dry mouth, nausea, and abdominal pain. A study by Settle4
found that these adverse effects are dose related. Compared with placebo,
which had a 4% discontinuation rate, buproprion had a discontinuation rate
of 9% at the 300 mg/d dosage and 11% at 450 mg/d dosage. We describe herein
a serum sickness–like reaction in a man taking bupropion.

SN  - 0098-7484
M3  - doi: 10-1001/pubs.JAMA-ISSN-0098-7484-282-19-jbk1117
UR  - http://dx.doi.org/10-1001/pubs.JAMA-ISSN-0098-7484-282-19-jbk1117
ER  -